| Literature DB >> 30248162 |
Abstract
Chronic pruritus remains a difficult condition to treat with many non-specific therapeutic options. Recent scientific discoveries have elucidated the physiology associated with pruritus. Combined with clinical and experimental trials with immune-modulatory agents, chronic pruritus now has novel treatment options with known mechanisms of action. This review goes over recent scientific progress in understanding the molecular mechanisms governing pruritus, the cross-talk between the immune and nervous systems that regulate itch, and central nervous pathways and projections affected by itch. In light of these recent discoveries, we briefly discuss a growing body of data from relevant clinical trials investigating immunomodulatory drugs targeting specific interleukin receptors (IL-4/13/31) and intracellular signaling (e.g., Janus kinase) pathways. We focus on the physiological processes that control this complex physical and emotional experience, as well as the role of newer drugs used to treat chronic itch.Entities:
Keywords: chronic pruritus; neuro-immune interaction; dorsal root ganglion; IL-4; IL-13; IL-31; IL-4Ra; dupilumab; ruxolitinib; tofacitinib; nemolizumab; Janus kinase
Mesh:
Substances:
Year: 2018 PMID: 30248162
Source DB: PubMed Journal: Skin Therapy Lett ISSN: 1201-5989